GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NextGen Biomed Ltd (XTAE:NXGN) » Definitions » Capex-to-Operating-Income

NextGen Biomed (XTAE:NXGN) Capex-to-Operating-Income : 0.00 (As of Jun. 2023)


View and export this data going back to 2000. Start your Free Trial

What is NextGen Biomed Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

NextGen Biomed's Capital Expenditure for the six months ended in Jun. 2023 was ₪-0.03 Mil. Its Operating Income for the six months ended in Jun. 2023 was ₪-2.12 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


NextGen Biomed Capex-to-Operating-Income Historical Data

The historical data trend for NextGen Biomed's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextGen Biomed Capex-to-Operating-Income Chart

NextGen Biomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - -

NextGen Biomed Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NextGen Biomed's Capex-to-Operating-Income

For the Medical Instruments & Supplies subindustry, NextGen Biomed's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextGen Biomed's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NextGen Biomed's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where NextGen Biomed's Capex-to-Operating-Income falls into.



NextGen Biomed Capex-to-Operating-Income Calculation

NextGen Biomed's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -3.581
=N/A

NextGen Biomed's Capex-to-Operating-Income for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.025) / -2.121
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextGen Biomed  (XTAE:NXGN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


NextGen Biomed Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of NextGen Biomed's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NextGen Biomed (XTAE:NXGN) Business Description

Traded in Other Exchanges
N/A
Address
Azrieli Center, Round Tower 22nd Floor, Tel Aviv, ISR, 6701101
NextGen Biomed Ltd is pharmaceutical company. It manufactures medical instruments. Its products include pain-free auto-injectors, lancet devices and personal use pain alleviators. It develops and markets medical equipments. Its product line include DPS-101, which is used for treatment for psoriasis. Its other product line include DPS-101 phase II/III is in clinical trial.